Next Article in Journal
A Review of the Effects of Olive Oil-Cooking on Phenolic Compounds
Next Article in Special Issue
Bioprospecting the Antibiofilm and Antimicrobial Activity of Soil and Insect Gut Bacteria
Previous Article in Journal
Polycation–Polyanion Architecture of the Intermetallic Compound Mg3−xGa1+xIr
Previous Article in Special Issue
Antimicrobial and Antioxidant Potential of Scenedesmus obliquus Microalgae in the Context of Integral Biorefinery Concept
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of Antibacterial Components in the Methanol-Phase Extract from Edible Herbaceous Plant Rumex madaio Makino and Their Antibacterial Action Modes

1
Key Laboratory of Quality and Safety Risk Assessment for Aquatic Products on Storage and Preservation (Shanghai), Ministry of Agriculture and Rural Affairs of the People’s Republic of China, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China
2
Key Laboratory for Food Science and Biotechnology of Hunan Province, College of Food Science and Technology, Hunan Agricultural University, Changsha 410128, China
*
Authors to whom correspondence should be addressed.
Submission received: 24 November 2021 / Revised: 7 January 2022 / Accepted: 12 January 2022 / Published: 20 January 2022
(This article belongs to the Special Issue Researches on Novel Antibacterial Agents)

Abstract

:
Outbreaks and prevalence of infectious diseases worldwide are some of the major contributors to morbidity and morbidity in humans. Pharmacophageous plants are the best source for searching antibacterial compounds with low toxicity to humans. In this study, we identified, for the first time, antibacterial components and action modes of methanol-phase extract from such one edible herbaceous plant Rumex madaio Makino. The bacteriostatic rate of the extract was 75% against 23 species of common pathogenic bacteria. The extract was further purified using the preparative high-performance liquid chromatography (Prep-HPLC) technique, and five separated componential complexes (CC) were obtained. Among these, the CC 1 significantly increased cell surface hydrophobicity and membrane permeability and decreased membrane fluidity, which damaged cell structure integrity of Gram-positive and -negative pathogens tested. A total of 58 different compounds in the extract were identified using ultra-HPLC and mass spectrometry (UHPLC-MS) techniques. Comparative transcriptomic analyses revealed a number of differentially expressed genes and various changed metabolic pathways mediated by the CC1 action, such as down-regulated carbohydrate transport and/or utilization and energy metabolism in four pathogenic strains tested. Overall, the results in this study demonstrated that the CC1 from R. madaio Makino are promising candidates for antibacterial medicine and human health care products.

1. Introduction

China is one of the richest countries in biodiversity, with very high levels of plant endemism [1]. Pharmacopoeia of the Peoples’ Republic of China (2020 Edition) contains 2711 species of Chinese herbal plants, which constitute a gold mine for exploiting medicine candidates and health care products [2]. For instance, R. madaio Makino is an edible, perennial and herbaceous plant that belongs to the Dicotyledoneae class, Polygonaceae family, and Rumex genus. According to the National Compilation of Chinese Herbal Medicine (1996 Edition), leaf and root tissues of R. madaio Makino can be used as medicine such as clearing heat and detoxification, removing blood stasis, and defecating and killing insects. Nevertheless, current studies on the antibacterial activity of R. madaio Makino are rare.
In this study, antibacterial components and action modes of methanol-phase extract from R. madaio Makino were for the first time identified. The objectives of this study were: (1) to extract bioactive substances from R. madaio Makino using the methanol and chloroform extraction (MCE) method, and determine their inhibition activity against 23 species of pathogenic bacteria; (2) to purify the methanol-phase extract from R. madaio Makino by preparation high-performance liquid chromatography (Prep-HPLC) analysis, and identify bioactive compounds in componential complex 1 (CC 1) using an ultra-HPLC and mass spectrometry (UHPLC-MS) technique; (3) to determine cell surface hydrophobicity, cell membrane permeability, fluidity, and the damage of four representative pathogenic strains treated with the CC 1; (4) to decipher possible molecular mechanisms underlying antibacterial activity by comparative transcriptomic analysis. The results of this study meet the increasing need for novel antibacterial agent candidates against common pathogenic bacteria.

2. Results and Discussion

2.1. Antibacterial Activity of Crude Extracts from R. madaio Makino

Antibacterial substances in fresh leaf and stem tissues of R. madaio Makino were extracted using the MCE method. The results showed that the water loss rate of the plant material was 93.32%, and extraction rates of the methanol phase and chloroform phase were 32.10% and 29.60%, respectively. Antibacterial activity of the crude extracts against 23 species of pathogenic bacteria was determined, most of which are common foodborne pathogens, and the results are presented in Table 1. The chloroform-phase crude extract from R. madaio Makino showed a bacteriostatic rate of 39%, inhibiting 2 species of Gram-positive and 11 species of Gram-negative pathogens (Table 1, Figure 1). Remarkably, the methanol-phase crude extract from R. madaio Makino inhibited the growth of 33 bacteria strains tested with a bacteriostatic rate of 75%, including 2 species of Gram-positive and 18 species of Gram-negative pathogens (Table 1). Based on the higher bacteriostatic rate (75%), the methanol-phase crude extract from R. madaio Makino was chosen for further analysis in this study.

2.2. Purification of the Methanol-Phase Crude Extract from R. madaio Makino

Large amounts of the methanol-phase crude extract from R. madaio Makino were further purified by the Prep-HPLC analysis. As shown in Figure 2, five obviously separated peaks (designated as componential complex, CCs 1 to 5) were observed by scanning at OD280 nm for 15 min.
These five single peaks were individually collected for antibacterial activity analysis. The results revealed that the CC 1 had strong inhibitory effects on Vibrio parahaemolyticus ATCC17802, Vibrio alginolyticus ATCC17749, Bacillus cereus A1-1, and V. parahaemolyticus B4-10. Moreover, the growth of the other four strains was also depressed, including V. parahaemolyticus ATCC33847, V. parahaemolyticus B3-13, V. parahaemolyticus B5-29, and Staphylococcus aureus ATCC6538 (Table 2). Among these, V. alginolyticus is an opportunistic pathogenic bacterium that can infect a broad range of marine host animals, including fish, crab and pearl oysters, and can also infect the human ear, soft tissue and wounded sites [3,4], while V. parahaemolyticus is a leading seafood-borne pathogen worldwide and can cause acute gastroenteritis and septicemia in humans [5]. B. cereus is a Gram-positive bacterium for food poisoning. This bacterium has been incriminated in clinical conditions such as anthrax-like progressive pneumonia, fulminant sepsis, and devastating central nervous system infections, particularly in immunosuppressed individuals, intravenous drug abusers, and neonates [6].
Conversely, the other four peaks (CCs 2 to 4) showed weak or no antibacterial activity, indicating that bioactive compounds in the methanol-phase extract from R. madaio Makino existed in the CC 1.
MIC values of the CC 1 were also determined, which was 64 μg/mL against V. alginolyticus ATCC17749 and V. parahaemolyticus ATCC17802; 128 μg/mL against B. cereus A1-1; and 256 μg/mL against V. parahaemolyticus B4-10.

2.3. Changed Bacterial Cell Surface Structure by the CC 1 Extract

To decipher possible mechanisms underlying bacteriostatic activity of the CC 1, the cell structure of the four highly inhibited strains were observed by the transmission electron microscope (TEM) analysis. As shown in Figure 3, in remarkable contrast to control groups whose cell surface structure was intact, showing rod cells, a flat surface, and a clear structure, bacterial cells in the treatment groups showed different degrees of contraction and rupture, some of which were deformed with obvious depressions, folds or cavities on the surface. For example, for the Gram-positive B. cereus A1-1, the 2 h treatment by the CC 1 resulted in the bacterial cell surface shrinking seriously, the flagella breaking, and some contents leaking. After being treated for 4 h, cell surface shrinkage was intensified, and more cells were ruptured. After being treated for 6 h, the cell structure was seriously damaged, a large number of contents exuded, and only a few cells still maintained rod shape (Figure 3A). For the Gram-negative V. parahaemolyticus ATCC17802, after being treated with the CC 1 for 2 h, its cell surface shrunk slightly, and pili structure was still visible. However, after being treated for 4 h, the cell surface shrinkage increased and the cell membrane folded. V. parahaemolyticus ATCC17802 cells were destroyed, seriously shrunk and deformed after being treated for 6 h (Figure 3C). These results indicated that the CC 1 from R. madaio Makino damaged the cell surface structure of the Gram-negative and Gram-positive pathogens.

2.4. Changed Bacterial Cell Surface Hydrophobicity, Cell Membrane Fluidity, Permeability, and Damage by the CC 1 from R. madaio Makino

Cell surface hydrophobicity plays an important role in the adhesion to abiotic and biological surfaces and infiltration of host tissue [7]. In this study, bacterial cell surface hydrophobicity of all four experimental groups was significantly increased (p < 0.05) when compared with the control groups (Figure 4A). The effect was highly enhanced with the increase in treatment time. For example, cell surface hydrophobicity was significantly increased in V. parahaemolyticus ATCC17802 (1.47-fold), V. parahaemolyticus B4-10 (1.62-fold) and B. cereus A1-1 (1.42-fold) after being treated with the CC1 for 2 h (p < 0.05), whereas a similar change was observed in the treatment group of V. alginolyticus ATCC17749 (1.48-fold) after being treated for 4 h. Moreover, the highest increase in cell surface hydrophobicity was observed in B. cereus A1-1 (3.75-fold) after being treated with the CC1 for 6 h (Figure 4A).
Membrane fluidity is also a key parameter of the bacterial cell membrane that undergoes quick adaptation in response to environmental challenges [8]. It has recently been regarded as an important factor in the antibacterial mechanism of membrane-targeting antibiotics [9]. In this study, compared with the control groups, there was no significant difference in cell membrane fluidity of V. parahaemolyticus ATCC17802 and B4-10, as well as V. alginolyticus ATCC17749 after being treated with the CC 1 for 2 h (p > 0.05). However, a significant decrease in membrane fluidity of these three strains was observed after the treatment for 4 h. Additionally, cell membrane fluidity significantly declined in B. cereus A1-1 (1.20-fold) treated with the CC 1 for 2 h, and sharply lost for 6 h (8.11-fold) (Figure 4B). The change of membrane lipid composition likely contributed to the observed membrane fluidity change to resist the lipid disorder effect by therapeutic agents [10].
The o-nitrophenyl-β-d-galactopyranoside (o-nitrophenyl)-β-d-galactopyranoside (ONPG) was used as a probe to monitor the inner cell membrane permeability of the four bacterial strains, and the results were illustrated in Figure 5. Different influence of the CC 1 from R. madaio Makino on inner cell membrane permeability was observed among the four treatment groups. For example, V. alginolyticus ATCC17749 did not change significantly in the inner cell membrane permeability after the treatment for 2 h (p > 0.05), whereas a significant increase was observed after being treated for 4 h (1.15-fold) and 6 h (1.18-fold), respectively (p < 0.05) (Figure 5).
N-Phenyl-1-naphthylamine (NPN) was used as a probe to monitor the bacterial outer membrane permeability. As shown in Figure 6, the outer membrane permeability in the four experimental groups were all highly increased after the treatment with the CC 1 for 2 h (p < 0.01). The highest increase was found in B. cereus A1-1 (6.06-fold) after being treated for 6 h, whereas an opposite pattern was observed in V. parahaemolyticus ATCC17802 (1.77-fold).
As shown in Figure 4C, when compared with the control groups, cell membrane damage rates of all four experimental groups significantly increased (p < 0.05), which raised with the increase in treatment time. Significant damage was observed in B. cereus A1-1 (2.95-fold) and V. parahaemolyticus B4-10 (2.21-fold) after being treated for 2 h, whereas a similar change was found in the other two strains treated for 4 h. Moreover, cell membrane damage of B. cereus A1-1 was the most severe among the four strains after being treated for 6 h (8.54-fold).
Taken together, these results demonstrated that the CC 1 from R. madaio Makino significantly increased bacterial cell surface hydrophobicity and membrane permeability and decreased membrane fluidity of V. parahaemolyticus ATCC17802, V. parahaemolyticus B4-10, V. alginolyticus ATCC17749, and B. cereus A1-1, consistent with the observed bacterial surface structure by the TEM analysis. The damaged cell surface and membrane structure integrity were beneficial for the CC1 to penetrate bacterial cell envelope to target intracellular processes.

2.5. Identification of Potential Antibacterial Compounds in the CC 1 from R. madaio Makino

The obtained CC 1 resolved in H2O was subjected to UHPLC-MS analysis. As shown in Table 3, a total of 58 different compounds were identified. The highest percentage of these compounds in the CC 1 was p-phenol ethanolamine (18.62%), followed by D-2-aminobutyric acid (9.46%), sucrose (7.01%), turanose (7.01%), and lactulose (7.01%). Some compounds with lower concentrations were also identified from the extract (0.83–0.07%), including a galactose 1-phosphate, L-glutamic acid, and kojibiose (Table 3). Phenols and organic acids have good antioxidant and antibacterial activities [11], while alkaloids can inhibit the formation of and/or disperse bacterial biofilms [12]. For example, the indole of alkaloids is a versatile heterocyclic compound with various pharmacological activities such as anticancer, anticonvulsant, antimicrobial, antitubercular, antimalarial, antiviral, antidiabetic and other miscellaneous activities. Indole also regulates various aspects of bacterial physiology, including spore formation, plasmid stability, resistance to drugs, biofilm formation and virulence [13]. Saccharides have been used to preserve foods for a long history by changing cell osmolarity to inhibit harmful bacterial growth. Kojibiose is a natural disaccharide comprising two glucose moieties linked by an α-1,2 glycosidic bond. It has been reported that Kojibiose can inhibit bacterial proliferation and have anti-inflammatory and antiviral activities [14,15]. In contrast, the certain content of the identified amino acids may not contribute to the observed antibacterial activity by the CC 1 from R. madaio Makino.

2.6. Differential Transcriptomes Mediated by the CC 1 from R. madaio Makino

To gain insights into the genome-wide gene expression changes mediated by the CC 1 from R. madaio Makino, we determined transcriptomes of the four bacterial strains treated for 6 h using Illumina RNA sequencing technology. A complete list of DEGs in the four strains was available in the NCBI SRA database (https://submit.ncbi.nlm.nih.gov/subs/bioproject/, accessed on 17 October 2021) under the accession number PRJNA767551. To validate the transcriptome data, we examined 32 representative DEGs (Table S2) by RT-qPCR analysis, and the resulting data were correlated with those yielded from the transcriptome analysis (Table S2).

2.6.1. The Major Altered Metabolic Pathways in V. alginolyticus ATCC17749

Approximately 6.73% (316/4698) of V. alginolyticus ATCC17749 genes were expressed differently in the experimental group compared with the control group. Among these, 238 genes showed higher transcription levels (FC ≥ 2.0), and 78 genes were down-regulated (FC ≤ 0.5). Based on the comparative transcriptomic analyses, 11 significantly changed metabolic pathways were identified, including valine, leucine and isoleucine degradation; nitrogen, histidine, tryptophan, glyoxylate and dicarboxylate metabolisms; quorum sensing (QS); lysine degradation; fatty acid degradation; amino sugar and nucleotide sugar metabolism; ABC transporters; and mitogen-activated protein kinase (MAPK) signal pathway (Figure 7).
Remarkably, approximately 60 DEGs involved in 10 changed metabolic pathways were significantly up-regulated in V. alginolyticus ATCC17749 (2.002- to 87.807-fold) (p < 0.05) (Table 4). For example, in the valine, leucine and isoleucine degradation, expression of nine DEGs were significantly up-regulated at the transcription level (2.117- to 4.619-fold) (p < 0.05); six DEGs encoding key enzymes in the histidine metabolism were also significantly up-regulated (2.001- to 3.187-fold) (p < 0.05); similarly, in the tryptophan metabolism, expression of three DEGs were significantly enhanced (2.123- to 5.154-fold) (p < 0.05); additionally, in the lysine degradation, expression of a transcriptional regulator (N646_3623) and an arginine/lysine/ornithine decarboxylase (N646_1979) were significantly up-regulated (2.972- to 3.332-fold) (p < 0.05). These four pathways are related to amino acid degradation metabolisms.
Meanwhile, eight DEGs in the nitrogen metabolism were also significantly up-regulated (2.193- to 87.807-fold) (p < 0.05), in which, specifically, one DEG encoding a hydroxylamine reductase (N646_0236) was greatly enhanced to express (87.807-fold).
ABC transporters are ATP-dependent efflux transporters to transport lipids, metabolites, exogenous substances and other small molecules out of the cell [16]. They are also the main type of transporters associated with bacterial multidrug resistance [17]. In this study, comparative transcriptome analysis revealed 23 DEGs in ABC transporters and QS that were significantly up-regulated in V. alginolyticus ATCC17749 (2.104- to 7.585-fold) (p < 0.05) (Table 4). ABC transporter can also catalyze the turnover of lipids in the lipid bilayer that play a critical role in the occurrence and functional maintenance of the cell membrane [18]. In this study, the up-regulated expression of these DEGs suggested that the treatment with the CC 1 from R. madaio Makino enhanced the bacterial pumping of exogenous and endogenous metabolites to eliminate cell damage.
In contrast, all DEGs in the MAPK signaling pathway were significantly inhibited (0.123- to 0.369-fold) (p < 0.05) (Table 4), which likely led to a highly toxic reactive oxygen species (ROS) accumulation and cell damage.

2.6.2. The Major Altered Metabolic Pathways in V. parahaemolyticus ATCC17802

Approximately 19.62% (917/4,674) of V. parahaemolyticus ATCC17802 genes were expressed differently in the experimental group compared with the control group. Among these, 128 genes showed higher transcription levels (FC ≥ 2.0), and 789 genes were down-regulated (FC ≤ 0.5). Comparative transcriptome analyses revealed 20 significantly changed metabolic pathways, including methane, nitrogen, glycerolipid, propanoate, sulfur, starch and sucrose, taurine and hypotaurine, phosphonate and phosphinate, and biotin metabolisms; glucagon, and hypoxia inducible factor-1 (HIF-1) signaling pathway; benzoate and ethylbenzene degradation; glycolysis/gluconeogenesis; flagellar assembly; apoptosis; bacterial chemotaxis; cationic antimicrobial peptide (CAMP) resistance; necroptosis, and RNA transport (Figure 8).
Notably, approximately 77 DEGs involved in 12 changed metabolic pathways were significantly down-regulated (0.05- to 0.491-fold) (p < 0.05) (Table 5). For example, in the glycolysis/gluconeogenesis, except for an up-regulated 2-oxo acid dehydrogenase subunit E2 (VP_RS18295), the other seven DEGs were significantly down-regulation (0.087- to 0.433-fold) (p < 0.05); in the propanoate metabolic pathway, express of four DEGs were significantly depressed (0.051- to 0.240-fold) (p < 0.05); in the starch and sucrose metabolisms, except for a 4-alpha-glucono transfer (VP_RS22910), the other five DEGs were significantly down-regulated (0.206- to 0.499-fold) (p < 0.05). These three metabolic pathways were related to carbohydrate metabolisms. Their overall down-regulation trend indicated inactive carbon source transportation and/or utilization, which likely resulted in insufficient energy supply.
Approximately 44 DEGs involved in six energy metabolism pathways in V. parahaemolyticus ATCC17802 were also significantly inhibited (p < 0.05). For example, the DEG encoding a pyruvate dehydrogenase complex dihydrolipoyllysine-residue acetyltransferase (VP_RS12210) was significantly down-regulated (0.331-fold), which connects glycolysis with tricarboxylic acid cycle (TCA) and plays a key role in glucose metabolism [19]. The down-regulation of this enzyme led to a decrease in ATP production and insufficient energy supply [20], which consequently affected bacterial growth and mobility.
The bacterial flagellum is a complex mobility machine with a diversity of roles in pathogenesis, including attachment, colonization, invasion, maintenance and post-infection dispersal in the host [21,22]. In this study, expression of 23 DEGs involved in three substructures of the flagellum, including the filament, hook and basal body [23], were significantly down-regulated at the transcriptional level in V. parahaemolyticus ATCC17802 (0.055- to 0.49-fold) (p < 0.05), which indicated the depressed flagellum assembly that led to inactive motility of V. parahaemolyticus ATCC17802. The 17 down-regulated DEGs in the bacterial chemotaxis [24] (0.101- to 0.491-fold) (p < 0.05) provided indirect evidence for this result.
Interestingly, 23 DEGs encoding type III secretory system (T3SS) components were also significantly down-regulated (0.055- to 0.490 -fold) (p < 0.05). T3SS enables pathogenic bacteria to directly inject effector proteins into host cells, facilitating bacterial colonization in the host [25]. This result suggested that the cytotoxicity of V. parahaemolyticus ATCC17802 was significantly reduced after being treated with the CC 1 from R. madaio Makino.
Additionally, in the cationic antimicrobial peptide (CAMP) resistance system, five DEGs were significantly inhibited (0.120- to 0.489-fold), including a multidrug efflux RND transporter permease subunit VmeD (VP_RS00200), a thiol: disulfide interchange protein DsbA/DsbL (VP_RS21260), an ATP-binding cassette domain-containing protein (VP_RS05670), a multidrug efflux RND transporter periplasmic adaptor subunit VmeC (VP_RS00205), and a phosphoethanolamine-lipid A transferase (VP_RS21300) (Table 5). These results indicated poor efficiency of multidrug efflux transport in V. parahaemolyticus ATCC17802 after being treated by the CC 1.
In contrast, five DEGs were significantly up-regulated (2.030- to 4.705-fold), e.g., a response regulator (VP_RS14060) and an envelope stress sensor histidine kinase CpxA (VP_RS14065) (Table 5).

2.6.3. The Major Altered Metabolic Pathways in V. parahaemolyticus B4-10

Approximately 16.75% (783/4674) of V. parahaemolyticus B4-10 genes were expressed differently in the experimental group when compared with the control group. Among these genes, 204 showed higher transcription levels (FC ≥ 2.0), and 579 genes were down-regulated (FC ≤ 0.5). Based on the comparative transcriptome analysis, five significantly changed metabolic pathways were identified, including styrene degradation, nitrogen metabolism, QS, folate biosynthesis, and histidine metabolism (Figure 9).
Similar to V. alginolyticus ATCC17749, the expression of 10 DEGs in the nitrogen metabolism were significantly up-regulated (2.129- to 107.754-fold) (p < 0.05) (Table 6). Notably, one DEG encoding a hydroxylamine reductase (VP_RS05780) was greatly up-regulated (107.754-fold). This enzyme can reduce hydroxylamine analogs such as methylhydroxylamine and hydroxyquinone as a scavenger of potentially toxic by-products of nitrate metabolism [26]. Moreover, in the histidine metabolism, four DEGs were highly up-regulated (5.106- to 10.231-fold) (Table 6). The enhanced nitrogen metabolism may have supplemented the energy supply in V. parahaemolyticus B4-10 after being treated by the CC 1.

2.6.4. The Major Altered Metabolic Pathways in B. cereus A1-1

Approximately 12.57% (720/5730) of B. cereus A1-1 genes were expressed differently in the experimental group. Among these genes, 178 showed higher transcription levels (FC ≥ 2.0), and 542 genes were down-regulated (FC ≤ 0.5). The comparative transcriptome analysis revealed 17 significantly changed metabolic pathways, including flagellar assembly; bacterial chemotaxis; two-component system (TCS); thiamine and nitrogen metabolisms; ABC transporters; arginine biosynthesis; fatty acid degradation; alanine, aspartate and glutamate metabolism; riboflavin metabolism; HIF-1 signaling pathway; glycolysis/gluconeogenesis; butanoate, pyrimidine, and propanoate metabolisms; benzoate degradation; and inositol phosphate metabolism (Figure 10).
Similar to the other bacterial strains tested, expression of 12 DEGs involved in the nitrogen metabolism and riboflavin metabolism were significantly up-regulated in B. cereus A1-1 (3.325- to 150.780-fold) (p < 0.05) (Table 7). Specifically, the DEG encoding a hydroxylamine reductase (BCN_RS16540) was also greatly enhanced to express in B. cereus A1-1 (150.780-fold).
Conversely, 69 DEGs involved in the flagellar assembly, bacterial chemotaxis, ABC transporters, and TCS were significantly down-regulated at the transcription level in B. cereus A1-1 (0.038- to 0.487-fold) (p < 0.05) (Table 7), similar to the other bacterial strains treated with the CC1. For example, in the flagellar assembly, expression of 19 DEGs were significantly depressed (0.038- to 0.438-fold) (p < 0.05); 9 DEGs in bacterial chemotaxis were significantly down-regulated (0.063- to 0.474-fold); and expression of 33 DEGs in ABC transporters were significantly inhibited (0.051- to 0.487-fold).
Approximately eight DEGs in the TCSs were significantly down-regulated. TCSs are widespread regulatory systems that can help bacteria to control their cellular functions and respond to a diverse range of stimuli [27]. In this study, in the HIF-1 signaling pathway, the expression of a L-lactate dehydrogenase (BCN_RS24725) was also significantly down-regulated (0.191-fold). These results indicated the inhibited signal transduction systems in B. cereus A1-1.
Additionally, 17 DEGs in the arginine biosynthesis, thiamine metabolism, and alanine, aspartate and glutamate metabolism were all significantly down-regulated (0.031- to 0.498-fold) (p < 0.05) (Table 7), which suggested the inhibited energy metabolism in B. cereus A1-1 after being treated by the CC 1 from R. madaio Makino.

3. Materials and Methods

3.1. Bacterial Strains and Culture Conditions

Bacterial strains and culture media used in this study are listed in Table S1. Bacterial culture media were purchased as described previously [28]. Vibrio strains were inoculated in media (pH 8.4–8.5) with 3.0% NaCl, while non-Vibrios in media (pH 7.0–7.2) with 1% NaCl [28].

3.2. Extraction of Bioactive Substances from R. madaio Makino

R. madaio Makino was collected in Lishui City (27°25′37″ N, 118°41′28″ E), Zhejiang Province, China in September of 2020. A 500 g of fresh leaf and stem tissues of R. madaio Makino was washed clean, dried at room temperature, and then freeze-dried using ALPHA 2-4 LD Plus Freeze Dryer (Martin Christ, Osterode, Germany) at −80 °C for 48 h. The freeze-dried material was crushed using FW-135 High-Speed Crusher (Beijing Kangtuo Medical Instruments Co., Ltd., Beijing, China) and passed through 300 mesh screen. Then, 10.0 g of the powder was mixed with 99-mL chloroform: methanol (2:1, v/v, analytical grade, Merck KGaA, Darmstadt, Germany) at a solid to liquid ratio of 1.10 (m/v) for 5 h [29]. A 60 mL of H2O (Analytical grade, Merck KGaA, Darmstadt,,Germany) was then added, fully mixed, and then sonicated using Scientz IID ULtrasonic Cell Crusher (SCIENT Z, Ningbo, China) at the following parameters: power: 300 W; ultrasonic on time: 1 s; ultrasonic off time: 1 s; working time: 20 min; and probe size: 6 mm. The sonicated mixture was filtered through 20–25 μm membrane (Shanghai Sangon Biological Engineeing Technology and Service Co., Ltd., Shanghai, China), and the filtration was collected for the secondary extraction. The methanol phase was separated from the chloroform phase and then individually evaporated, concentrated on pasting using Rotary Evaporator (IKA, Staufen, Germany).

3.3. Antimicrobial Susceptibility Assay

Susceptibility of bacterial strains (Table S1) to the extracts from R. madaio Makino was determined according to the method issued by Clinical and Laboratory Standards Institute (CLSI) (2018, CLSI, M100-S23) using Mueller-Hinton (M-H) agar (CM337) and Mueller-Hinton broth (M391) (OXOID, Basingstoke, UK). Briefly, a 10 μL of crude extracts (500 μg/mL) was added onto each blank disc (6 mm, OXOID, Basingstoke, UK) on MH ager plates. The gentamicin disc (10 μg, OXOID, Basingstoke, UK) was used as a positive control, while the methanol-phase with water and chloroform-phase with ethanol was a negative control, respectively. The plates were incubated at 37 °C for 12 h. Bacteriostatic activity was evaluated by measuring diameters of bacteriostatic circles.
Broth dilution testing (microdilution) (2018, CLSI, M100-S18) was used to determine MICs of the extracts. Briefly, a 100 μL/well of the extracts (1024 μg/mL) was serially diluted, mixed with 100 μL/well of Mueller-Hinton broth (CM337) and 10 μL/well of bacteria strain (1.5 × 106 colony-forming unit (CFU)/mL), and then incubated at 37 °C for 12 h [30]. The MIC was defined as the lowest concentration of a particular antibacterial agent that inhibits bacterial growth (2018, CLSI, M100-S18). The standard solution of gentamicin (100 μg/mL) was purchased from National Standard Material Information Center, Beijing, China.

3.4. Prep-HPLC Analysis

Aliquots (10 mg/mL) of freeze-dried samples resolved in H2O (Analytical grade, Merck KGaA, Darmstadt, Germany) were centrifuged at 12,000 rpm for 20 min. The supernatant was filtered through 0.22 µm membrane (Sangon, Shanghai, China), and the filtration was collected for further analysis. Prep-HPLC was run using Waters 2707 (Waters, Milford, Massachusetts, USA) linked with UPLC Sunfire C18 column (5 μm, 10 × 250 mm) (Waters, Massachusetts, USA) at the following parameters: column temperature, 40 °C; injection volume, 100 μL; and mobile phase of methanol (eluent A) and water (eluent B) at a flow rate of 4 mL/min (isocratic elution: 0–15 min, 20% eluent A and 80% eluent B). Photo-diode array (PDA) spectra were measured in the wavelength ranging from 200 to 600 nm.

3.5. UHPLC–MS Analysis

The UHPLC–MS analysis was carried out using EXIONLC System (Sciex, Framingham, MA, USA) by Shanghai Hoogen Biotech, Shanghai, China using the parameters as described previously [31]. The mobile phase A contained 0.1% formic acid in H2O (v/v), and mobile phase B was acetonitrile (Merck KGaA, Darmstadt, Germany); column temperature: 40 °C; auto-sampler temperature: 4 °C; injection volume: 2 μL. Typical ion source parameters were: IonSpray voltage: +5500/−4500 V; curtain gas: 35 psi; temperature: 400 °C; ion source Gas 1:60 psi; ion source Gas 2: 60 psi; and declustering potential (DP): ±100 V. The SCIEX Analyst Work Station Software (Version 1.6.3) was employed for multiple reaction monitoring (MRM) data acquisition and processing. In-house R program and database were applied for peak detection and annotation (Shanghai Hoogen Biotech, Shanghai, China).

3.6. Transmission Electron Microscope (TEM) Assay

Samples for TEM analysis were prepared according to the method described previously [32]. Briefly, 1 × MIC concentration of CC 1 from R. madaio Makino was added in bacterial culture (5 mL) at middle logarithmic growth phase (mid-LQP), and incubated at 37 °C for 2 h, 4 h and 6 h, respectively. A 1.5 mL of the cell suspension were collected, washed, fixed, and observed using SU5000 transmission electron microscope (Hitachi, Tokyo, Japan, 5.0 kV, ×30,000) [32].

3.7. Bacterial Cell Surface Hydrophobicity, Membrane Fluidity and Damage Assays

Bacterial cell surface hydrophobicity and membrane fluidity were measured according to the methods by Krausova et al. [33] and Kuhry et al. [34], respectively. In the former method, 1 mL of 98% cetane (Sangon, Shanghai, China) was added into 1 mL of bacterial cell suspension (OD600 nm values of 0.55 to 0.60) and rotated for 1 min and then stood at room temperature for 30 min. The absorbance of the aqueous phase was measured at OD600 nm using BioTek Synergy 2 (BioTek, Burlington, VT, USA). To measure the membrane fluidity, a 200 μL/well of bacterial suspension was mixed with 2 μL of 10 mM 1,6-diphenyl-1,3,5-hexatriene (DPH) (Sangon, China), and the change of fluorescence intensity of each well was measured at excitation light wavelength of 362 nm and emission light wavelength of 427 nm using BioTek Synergy 2 (BioTek, Burlington, VT, USA).
Cell membrane damage was examined according to the method described previously [32]. Briefly, the bacterial cell suspension was double-dyed using propidium iodide (PI, 10 mM final concentration) (Sangon, China), and 5(6)-carboxydiacetate fluorescein succinimidyl ester (CFDA, 10 mM final concentration) (Beijing Solarbio Science & Technology Co. Ltd., Beijing, China), and determined using Flow Cytometer BD FACSVerse™ (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) [32].

3.8. Cell Membrane Permeability Analysis

Bacterial culture at the mid-LGS was mixed with 1 × MIC concentration of the CC 1 from R. madaio Makino and then incubated at 37 °C for 2 h, 4 h and 6 h. Outer membrane permeability was measured according to the method described previously [35]. Briefly, a 200 μL/well of bacterial cell suspension was mixed with 2 μL/well of 10 mm NPN solution (Sangon, Shanghai, China). The excitation and emission wavelengths were set at 350 nm and 420 nm, respectively, and recorded using BioTek Synergy 2 (BioTek, Burlington, VT, USA) [35].
Inner membrane permeability was measured according to the method described previously [36]. Briefly, a 200 μL/well of bacterial cell suspension was mixed with 2.5 μL/well of 10 mm ONPG solution (Sangon, Shanghai, China). The cell mixture was incubated at 37 °C and measured for each well at OD415 nm using BioTek Synergy 2 (BioTek, Burlington, VT, USA) every 30 min for 5 h, which was marked as OD1, while OD2 generated from the untreated bacterial suspension was used as a negative control [36].

3.9. Illumina RNA Sequencing

Bacterial culture at the mid-LGP was treated with 1 × MIC concentration of the CC 1 from R. madaio Makino for 6 h. Total RNA was prepared using RNeasy Protect Bacteria Mini Kit (QIAGEN Biotech Co. Ltd., Frankfurt, Germany) and QIAGEN RNeasy Mini Kit (QIAGEN). DNA was removed from the samples using RNase-Free DNase Set (QIAGEN). Three independently prepared RNA samples were used for each Illumina RNA-sequencing analysis. Illumina sequencing was conducted by Shanghai Majorbio Bio-pharm Technology Co. Ltd. (Shanghai, China) using Illumina HiSeq 2500 platform (Illumina, Santiago, CA, USA). High quality reads that passed the Illumina quality filters were used for sequence analyses [32].

3.10. Reverse Transcription Real Time-Quantitative PCR (RT-qPCR) Assay

Total RNA extraction, reverse transcription reactions, and relative quantitative PCR reactions were performed using the same kits and instrument according to the method described previously [31]. The 16S rRNA gene was used as the internal reference gene, and 2−ΔΔCt method was used to calculate relative expression of genes. Oligonucleotide primers used for the RT-qPCR were synthesized by Sangon, Shanghai, China.

3.11. Data Analysis

Expression of each gene was calculated using RNA-Seq by Expectation-Maximization (RSEM, http://deweylab.github.io/RSEM/, accessed on 17 October 2021). Genes with the criteria, fold-changes ≥ 2.0 or ≤0.5, and p-values < 0.05 relative to the control were defined as DEGs. These DEGs were used for gene set enrichment analysis (GSEA) against the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (https://www.genome.jp/kegg/, accessed on 17 October 2021). Significantly changed GSEA were identified when the enrichment test p-value fell below 0.05 [32]. All tests were performed in triplicates. The data were analyzed using SPSS statistical analysis software version 17.0 (SPSS Inc., Armonk, NY, USA).

4. Conclusions

In this study, we identified, for the first time, antibacterial components and action modes of methanol-phase extract from one edible herbaceous plant R. madaio Makino. The bacteriostatic rate of the extract was 75% against 23 species of common pathogenic bacteria, which was higher than that of the chloroform-phase extract (39%). The methanol-phase extract was further purified using the Prep-HPLC technique, and five separated CCs were obtained. Among these, the CC 1 from R. madaio Makino significantly increased bacterial cell surface hydrophobicity and membrane permeability and decreased membrane fluidity of Gram-positive and Gram-negative pathogens, such as V. parahaemolyticus ATCC17802, V. parahaemolyticus B4-10, V. alginolyticus ATCC17749, and B. cereus A1-1. The damaged cell surface and membrane structure integrity facilitated the CC1 to penetrate bacterial cell envelope to target intracellular processes. A total of 58 different compounds in the extract were identified using UHPLC–MS technique. Comparative transcriptomic analyses revealed a number of differentially expressed genes (DGEs) and various changed metabolic pathways mediated by the CC1 action, such as down-regulation of carbohydrate transport and/or utilization, and energy metabolism; upward regulation of amino acid and fatty acid degradation, and nitrogen metabolism; and inactive flagellar assembly and mobility in the four bacterial strains. Taken, the results in this study demonstrated that the CC1 from R. madaio Makino are promising candidates for antibacterial medicine and human health care products.

Supplementary Materials

The following supporting information can be downloaded at. Table S1: Bacterial strains and media used in this study; Table S2: Expression of representative DEGs by RT-qPCR assay.

Author Contributions

Y.L.: investigation, data curation, and writing—original draft preparation; L.Y.: data analysis; P.L.: assistance in the instrument for the extract preparation; Y.J.: discussion; S.Q.: supervision, and discussion; L.C.: funding acquisition, conceptualization, and writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by Shanghai Municipal Science and Technology Commission, grant number 17050502200, and National Natural Science Foundation of China, grant number 31671946.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

A complete list of DEGs in the four strains were available in the NCBI SRA database (https://submit.ncbi.nlm.nih.gov/subs/bioproject/, accessed on 17 October 2021) under the accession number PRJNA767551.

Acknowledgments

The authors are grateful to Yaping Wang and Ling Ni for their help in the extract preparation and to Zhengke Shen for her assistance in the manuscript preparation.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the methanol-phase extract from R. malaio Makino are available from the authors by request.

References

  1. Huang, J.; Huang, J.; Lu, X.; Ma, K. Diversity distribution patterns of Chinese endemic seed plant species and their implications for conservation planning. Sci. Rep. 2016, 6, 33913. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Xu, X.; Xu, H.; Shang, Y.; Zhu, R.; Hong, X.; Song, Z.; Yang, Z. Development of the general chapters of the Chinese Pharmacopoeia 2020 edition: A review. J. Pharm. Anal. 2021, 11, 398–404. [Google Scholar] [CrossRef] [PubMed]
  3. Ye, Y.; Xia, M.; Mu, C.; Li, R.; Wang, C. Acute metabolic response of Portunus trituberculatus to Vibrio alginolyticus infection. Aquaculture 2016, 463, 201–208. [Google Scholar] [CrossRef]
  4. Lv, T.; Song, T.; Liu, H.; Peng, R.; Jiang, X.; Zhang, W.; Han, Q. Isolation and characterization of a virulence related Vibrio alginolyticus strain Wz11 pathogenic to Cuttlefish, Sepia pharaonis. Microb. Pathog. 2019, 126, 165–171. [Google Scholar] [CrossRef]
  5. Li, L.; Meng, H.; Gu, D.; Li, Y.; Jia, M. Molecular mechanisms of Vibrio parahaemolyticus pathogenesis. Microbiol. Res. 2019, 222, 43–51. [Google Scholar] [CrossRef]
  6. Bottone, E.J. Bacillus cereus, a volatile human pathogen. Clin. Microbiol. Rev. 2010, 23, 382–398. [Google Scholar] [CrossRef] [Green Version]
  7. Danchik, C.; Casadevall, A. Role of cell surface hydrophobicity in the pathogenesis of medically-significant fungi. Front. Cell. Infect. Microbiol. 2020, 10, 594973. [Google Scholar] [CrossRef] [PubMed]
  8. Ma, S.; Ding, L.; Hu, H.; Ma, H.; Xu, K.; Huang, H.; Geng, J.; Ren, H. Cell membrane characteristics and microbial population distribution of MBBR and IFAS with different dissolved oxygen concentration. Bioresour. Technol. 2018, 265, 17–24. [Google Scholar] [CrossRef] [PubMed]
  9. Aqawi, M.; Sionov, R.V.; Gallily, R.; Friedman, M.; Steinberg, D. Anti-bacterial properties of cannabigerol toward Streptococcus mutans. Front. Microbiol. 2021, 12, 656471. [Google Scholar] [CrossRef] [PubMed]
  10. Bajpai, V.K.; Sharma, A.; Baek, K.-H. Antibacterial mode of action of Ginkgo biloba leaf essential oil: Effect on morphology and membrane permeability. Bangl. J. Pharmacol. 2015, 10, 337. [Google Scholar] [CrossRef] [Green Version]
  11. Zhang, D.; Nie, S.; Xie, M.; Hu, J. Antioxidant and antibacterial capabilities of phenolic compounds and organic acids from Camellia oleifera cake. Food Sci. Biotechnol. 2020, 29, 17–25. [Google Scholar] [CrossRef]
  12. Cushnie, T.P.T.; Cushnie, B.; Lamb, A.J. Alkaloids: An overview of their antibacterial, antibiotic-enhancing and antivirulence activities. Int. J. Antimicrob. Agents 2014, 44, 377–386. [Google Scholar] [CrossRef] [PubMed]
  13. Kumari, A.; Singh, R.K. Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives. Bioorg. Chem. 2019, 89, 103021. [Google Scholar] [CrossRef] [PubMed]
  14. Wang, M.; Wu, J.; Wu, D. Cloning and expression of the sucrose phosphorylase gene in Bacillus subtilis and synthesis of kojibiose using the recombinant enzyme. Microb. Cell Fact. 2018, 17, 23. [Google Scholar] [CrossRef] [Green Version]
  15. Garcia, C.A.; Gardner, J.G. Bacterial α-diglucoside metabolism: Perspectives and potential for biotechnology and biomedicine. Appl. Microbiol. Biotechnol. 2021, 105, 4033–4052. [Google Scholar] [CrossRef] [PubMed]
  16. Jarzyniak, K.; Banasiak, J.; Jamruszka, T.; Pawela, A.; Di Donato, M.; Novák, O.; Geisler, M.; Jasiński, M. Early stages of legume-rhizobia symbiosis are controlled by ABCG-mediated transport of active cytokinins. Nat. Plants 2021, 7, 428–436. [Google Scholar] [CrossRef] [PubMed]
  17. Tsao, S.; Rahkhoodaee, F.; Raymond, M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother. 2009, 53, 1344–1352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Tarling, E.J.; de Aguiar Vallim, T.Q.; Edwards, P.A. Role of ABC transporters in lipid transport and human disease. Trends Endocrinol. Metab. 2013, 24, 342–350. [Google Scholar] [CrossRef] [Green Version]
  19. Whitley, M.J.; Arjunan, P.; Nemeria, N.S.; Korotchkina, L.G.; Park, Y.H.; Patel, M.S.; Jordan, F.; Furey, W. Pyruvate dehydrogenase complex deficiency is linked to regulatory loop disorder in the αV138M variant of human pyruvate dehydrogenase. J. Biol. Chem. 2018, 293, 13204–13213. [Google Scholar] [CrossRef] [Green Version]
  20. Aquilano, K.; Vigilanza, P.; Rotilio, G.; Ciriolo, M.R. Mitochondrial damage due to SOD1 deficiency in SH-SY5Y neuroblastoma cells: A rationale for the redundancy of SOD1. FASEB J. 2006, 20, 1683–1685. [Google Scholar] [CrossRef] [Green Version]
  21. Hajam, I.A.; Dar, P.A.; Shahnawaz, I.; Jaume, J.C.; Lee, J.H. Bacterial flagellin-a potent immunomodulatory agent. Exp. Mol. Med. 2017, 49, e373. [Google Scholar] [CrossRef]
  22. Nedeljković, M.; Sastre, D.E.; Sundberg, E.J. Bacterial flagellar filament: A supramolecular multifunctional nanostructure. Int. J. Mol. Sci. 2021, 22, 7521. [Google Scholar] [CrossRef] [PubMed]
  23. Carroll, B.L.; Nishikino, T.; Guo, W.; Zhu, S.; Kojima, S.; Homma, M.; Liu, J. The flagellar motor of Vibrio alginolyticus undergoes major structural remodeling during rotational switching. Elife 2020, 9. [Google Scholar] [CrossRef] [PubMed]
  24. Ahmad, F.; Zhu, D.; Sun, J. Bacterial chemotaxis: A way forward to aromatic compounds biodegradation. Environ. Sci. Eur. 2020, 32, 52. [Google Scholar] [CrossRef]
  25. LeBlanc, M.A.; Fink, M.R.; Perkins, T.T.; Sousa, M.C. Type III secretion system effector proteins are mechanically labile. Proc. Natl. Acad. Sci. USA 2021, 118. [Google Scholar] [CrossRef] [PubMed]
  26. van den Berg, W.A.; Hagen, W.R.; van Dongen, W.M. The hybrid-cluster protein (‘prismane protein’) from Escherichia coli. Characterization of the hybrid-cluster protein, redox properties of the [2Fe-2S] and [4Fe-2S-2O] clusters and identification of an associated NADH oxidoreductase containing FAD and [2Fe-2S]. Eur. J. Biochem. 2000, 267, 666–676. [Google Scholar] [CrossRef]
  27. Xue, M.; Raheem, M.A.; Gu, Y.; Lu, H.; Song, X.; Tu, J.; Xue, T.; Qi, K. The KdpD/KdpE two-component system contributes to the motility and virulence of avian pathogenic Escherichia coli. Res. Vet. Sci. 2020, 131, 24–30. [Google Scholar] [CrossRef]
  28. Xu, M.; Fu, H.; Chen, D.; Shao, Z.; Zhu, J.; Alali, W.Q.; Chen, L. Simple visualized detection method of virulence-associated genes of Vibrio cholerae by loop-mediated isothermal amplification. Front. Microbiol. 2019, 10, 2899. [Google Scholar] [CrossRef] [PubMed]
  29. Wang, Y.; Chen, L.; Pandak, W.M.; Heuman, D.; Hylemon, P.B.; Ren, S. High glucose Induces lipid accumulation via 25-Hydroxycholesterol DNA-CpG methylation. iScience 2020, 23, 101102. [Google Scholar] [CrossRef]
  30. Chen, D.; Li, X.; Ni, L.; Xu, D.; Xu, Y.; Ding, Y.; Xie, L.; Chen, L. First experimental evidence for the presence of potentially toxic Vibrio cholerae in Snails, and virulence, cross-resistance and genetic diversity of the bacterium in 36 species of aquatic food animals. J. Antibiot. 2021, 10, 412. [Google Scholar] [CrossRef]
  31. Shan, X.; Fu, J.; Li, X.; Peng, X.; Chen, L. Comparative proteomics and secretomics revealed virulence, and coresistance-related factors in non O1/O139 Vibrio cholerae recovered from 16 species of consumable aquatic animals. J. Proteom. 2021, 251, 104408. [Google Scholar] [CrossRef] [PubMed]
  32. Yang, L.; Wang, Y.; Yu, P.; Ren, S.; Zhu, Z.; Jin, Y.; Yan, J.; Peng, X.; Chen, L. Prophage-related gene VpaChn25_0724 contributes to cell membrane Integrity and growth of Vibrio parahaemolyticus CHN25. Front. Cell. Infect. Microbiol. 2020, 10, 595709. [Google Scholar] [CrossRef] [PubMed]
  33. Krausova, G.; Hyrslova, I.; Hynstova, I. In vitro evaluation of adhesion capacity, hydrophobicity, and auto-aggregation of newly isolated potential probiotic strains. Fermentation 2019, 5, 100. [Google Scholar] [CrossRef] [Green Version]
  34. Kuhry, J.G.; Duportail, G.; Bronner, C.; Laustriat, G. Plasma membrane fluidity measurements on whole living cells by fluorescence anisotropy of trimethylammoniumdiphenylhexatriene. Biochim. Biophys Acta. 1985, 845, 60–67. [Google Scholar] [CrossRef]
  35. Wang, Z.; Qin, Q.; Zheng, Y.; Li, F.; Zhao, Y.; Chen, G.-Q. Engineering the permeability of Halomonas bluephagenesis enhanced its chassis properties. Metab. Eng. 2021, 67, 53–66. [Google Scholar] [CrossRef] [PubMed]
  36. Huang, B.; Liu, X.; Li, Z.; Zheng, Y.; Wai Kwok Yeung, K.; Cui, Z.; Liang, Y.; Zhu, S.; Wu, S. Rapid bacteria capturing and killing by AgNPs/N-CD@ZnO hybrids strengthened photo-responsive xerogel for rapid healing of bacteria-infected wounds. Chem. Eng. J. 2021, 414, 128805. [Google Scholar] [CrossRef]
Figure 1. Inhibition activity of the methanol-phase crude extract from R. madaio Makino against the four representative bacterial strains. (A-1): B. cereus A1-1; (B-1): V. alginolyticus ATCC17749; (C-1): V. Parahaemolyticus ATCC17802; and (D-1): V. Parahaemolyticus B4-10. (A-2D-2): negative control, respectively.
Figure 1. Inhibition activity of the methanol-phase crude extract from R. madaio Makino against the four representative bacterial strains. (A-1): B. cereus A1-1; (B-1): V. alginolyticus ATCC17749; (C-1): V. Parahaemolyticus ATCC17802; and (D-1): V. Parahaemolyticus B4-10. (A-2D-2): negative control, respectively.
Molecules 27 00660 g001
Figure 2. The Prep−HPLC diagram of purifying the methanol-phase crude extract from R. madaio Makino.
Figure 2. The Prep−HPLC diagram of purifying the methanol-phase crude extract from R. madaio Makino.
Molecules 27 00660 g002
Figure 3. The TEM observation of cell surface structure of the four bacterial strains treated with the CC1 for different times. (A): B. cereus A1-1; (B): V. alginolyticus ATCC17749; (C): V. Parahaemolyticus ATCC17802; and (D): V. Parahaemolyticus B4-10.
Figure 3. The TEM observation of cell surface structure of the four bacterial strains treated with the CC1 for different times. (A): B. cereus A1-1; (B): V. alginolyticus ATCC17749; (C): V. Parahaemolyticus ATCC17802; and (D): V. Parahaemolyticus B4-10.
Molecules 27 00660 g003aMolecules 27 00660 g003b
Figure 4. Effects of the CC 1 from R. madaio Makino on cell surface hydrophobicity, membrane fluidity and damage of the four bacterial strains. (A): cell surface hydrophobicity; (B): cell membrane fluidity; and (C): cell membrane damage. The results were represented as the mean ± standard deviation of three repetitions. *: p < 0.05; **: p < 0.01; and ***: p < 0.001.
Figure 4. Effects of the CC 1 from R. madaio Makino on cell surface hydrophobicity, membrane fluidity and damage of the four bacterial strains. (A): cell surface hydrophobicity; (B): cell membrane fluidity; and (C): cell membrane damage. The results were represented as the mean ± standard deviation of three repetitions. *: p < 0.05; **: p < 0.01; and ***: p < 0.001.
Molecules 27 00660 g004
Figure 5. Effects of the CC 1 from R. madaio Makino on inner cell membrane permeability of the four bacterial strains. (A): B. cereus A1-1; (B): V. alginolyticus ATCC17749; (C): V. Parahaemolyticus ATCC17802; and (D): V. Parahaemolyticus B4-10.
Figure 5. Effects of the CC 1 from R. madaio Makino on inner cell membrane permeability of the four bacterial strains. (A): B. cereus A1-1; (B): V. alginolyticus ATCC17749; (C): V. Parahaemolyticus ATCC17802; and (D): V. Parahaemolyticus B4-10.
Molecules 27 00660 g005
Figure 6. Effects of the CC 1 from R. madaio Makino on outer cell membrane permeability of the four bacterial strains. The results were represented as the mean ± standard deviation of three repetitions. **: p < 0.01; ***: p < 0.001.
Figure 6. Effects of the CC 1 from R. madaio Makino on outer cell membrane permeability of the four bacterial strains. The results were represented as the mean ± standard deviation of three repetitions. **: p < 0.01; ***: p < 0.001.
Molecules 27 00660 g006
Figure 7. The 11 significantly altered metabolic pathways in V. alginolyticus ATCC17749 mediated by the CC 1 from R. madaio Makino.
Figure 7. The 11 significantly altered metabolic pathways in V. alginolyticus ATCC17749 mediated by the CC 1 from R. madaio Makino.
Molecules 27 00660 g007
Figure 8. The 20 significantly altered metabolic pathways in V. parahaemolyticus ATCC17802 mediated by the CC 1 from R. madaio Makino.
Figure 8. The 20 significantly altered metabolic pathways in V. parahaemolyticus ATCC17802 mediated by the CC 1 from R. madaio Makino.
Molecules 27 00660 g008
Figure 9. The 5 significantly altered metabolic pathways in V. parahaemolyticus B4-10 mediated by the CC 1 from R. madaio Makino.
Figure 9. The 5 significantly altered metabolic pathways in V. parahaemolyticus B4-10 mediated by the CC 1 from R. madaio Makino.
Molecules 27 00660 g009
Figure 10. The 17 significantly altered metabolic pathways in B. cereus A1-1 mediated by the CC 1 from R. madaio Makino.
Figure 10. The 17 significantly altered metabolic pathways in B. cereus A1-1 mediated by the CC 1 from R. madaio Makino.
Molecules 27 00660 g010
Table 1. Antibacterial activity of crude extracts from R. madaio Makino.
Table 1. Antibacterial activity of crude extracts from R. madaio Makino.
pStrainInhibition Zone (Diameter, mm)MIC (μg/mL)
CPEMPECPEMPE
Aeromonas hydrophila ATCC3565411.30 ± 0.47126
Bacillus cereus A1-114.70 ± 1.2532
Enterobacter cloacae ATCC130477.90 ± 0.0513.00 ± 0.8651264
Enterobacter cloacae8.30 ± 0.24512
Escherichia coli ATCC8739
Escherichia coli ATCC25922
Escherichia coli K129.30 ± 1.25128
Enterobacter sakazakii CMCC454018.90 ± 0.148.70 ± 0.47256512
Listeria monocytogenes ATCC191159.80 ± 0.17256
Pseudomonas aeruginosa ATCC90279.30 ± 0.94256
Pseudomonas aeruginosa ATCC278539.00 ± 0.21256
Salmonella choleraesuis ATCC133129.70 ± 0.94256
Salmonella paratyphi-A CMCC500938.70 ± 0.949.40 ± 0.43512256
Salmonella typhimurium ATCC156118.90 ± 0.1714.00 ± 0.8225632
Salmonella8.20 ± 0.1720.30 ± 0.475128
Shigella dysenteriae CMCC51252
Shigella flexneri CMCC5157210.00 ± 0.00128
Shigella flexneri ATCC12022
Shigella flexneri CMCC51574
Shigella sonnei ATCC25931
Shigella sonnet CMCC515929.40 ± 0.298.10 ± 0.05256512
Staphylococcus aureus ATCC2592310.60 ± 0.428.10 ± 0.29128512
Staphylococcus aureus ATCC80958.00 ± 0.057.30 ± 0.215121024
Staphylococcus aureus ATCC292137.20 ± 0.081024
Staphylococcus aureus ATCC653810.00 ± 0.8210.00 ± 2.16256256
Staphylococcus aureus ATCC6538P10.50 ± 0.41128
Staphylococcus aureus7.00 ± 0.008.50 ± 0.411024512
Vibrio alginolyticus ATCC1774924.30 ± 1.254
Vibrio alginolyticus ATCC33787
Vibrio cholerae Q10-54
Vibrio cholerae b10-499.00 ± 0.24256
Vibrio cholerae GIM1.44910.30 ± 0.3610.50 ± 0.41256128
Vibrio fluvialis ATCC3380911.30 ± 0.477.90 ± 0.09128512
Vibrio harvey ATCC BAA-11178.00 ± 0.05512
Vibrio harveyi ATCC33842
Vibrio metschnikovii ATCC7000408.40 ± 0.42512
Vibrio mimicus bio-567599.20 ± 0.1213.00 ± 0.8251264
Vibrio parahaemolyticus B3-1310.50 ± 0.419.10 ± 0.12128256
Vibrio parahaemolyticus B4-1010.30 ± 0.47128
Vibrio parahaemolyticus B5-2912.30 ± 0.9464
Vibrio parahaemolyticus B9-358.30 ± 0.21512
Vibrio parahaemolyticus ATCC1780213.70 ± 0.94128
Vibrio parahaemolyticus ATCC3384713.00 ± 0.0064
Vibrio vulnificus ATCC2756211.70 ± 1.258.70 ± 0.47128256
Note: CPE: chloroform phase extract. MPE: methanol phase extract. —: no bacteriostasis activity. Inhibition zone: diameter includes the disk diameter (6 mm). MIC: minimum inhibitory concentration. Values are means ± S.D. of three parallel measurements.
Table 2. Antibacterial activity of the CC 1 from R. madaio Makino.
Table 2. Antibacterial activity of the CC 1 from R. madaio Makino.
StrainInhibition Zone (Diameter, mm)MIC (μg/mL)
B. cereus A1-110.30 ± 0.24128
S. typhimurium ATCC156117.90 ± 0.22512
S. aureus ATCC65387.00 ± 0.051024
V. alginolyticus ATCC1774911.20 ± 0.2164
V. parahaemolyticus ATCC1780211.10 ± 0.0864
V. parahaemolyticus ATCC338477.90 ± 0.25256
V. parahaemolyticus B3-137.10 ± 0.09512
V. parahaemolyticus B4-109.40 ± 0.26256
V. parahaemolyticus B5-298.10 ± 0.12512
Note: MIC: minimum inhibitory concentration.
Table 3. Compounds identified in the CC 1 from R. madaio Makino by the UHPLC–MS analysis.
Table 3. Compounds identified in the CC 1 from R. madaio Makino by the UHPLC–MS analysis.
Peak
No.
Identified CompoundCompound NatureRt (min)FormulaExact MassPeak Area (%)
1p-OctopamineBiogenic amine3.84C8H11NO2153.0818.62
2D-alpha-Aminobutyric acidAmino acids and derivatives0.65C4H9NO2103.069.46
3SucroseCarbohydrates0.89C12H22O11342.127.01
4TuranoseCarbohydrates0.79C12H22O11342.127.01
5LactuloseOrganooxygen compounds0.77C12H22O11342.127.01
6L-ArginineAmino acids and derivatives0.60C6H14N4O2174.114.98
7L-Lysine; L-GlutamineAmino acids and derivatives0.64C6H14N2O2146.114.68
8D-GlutamineAmino acids and derivatives0.66C5H10N2O3146.074.68
9(2E)-Decenoyl-ACPCarboxylic acids and derivatives1.47C6H11NO2129.083.14
10O-AcetylethanolamineAlkaloids0.67C4H9NO2103.063.00
11L-Pipecolic acidAmino acids and derivatives0.69C6H11NO2129.082.48
12Pyrrolidonecarboxylic acidAmino acids and derivatives0.67C5H7NO3129.042.48
13D-MaltoseCarbohydrates0.76C12H22O11342.121.86
14TrigonellineAlkaloids0.82C7H7NO2137.051.74
15IndoleAlkaloids3.82C8H7N117.061.66
16Uridine 5’-diphospho-d-glucoseCarbohydrates0.71C15H24N2O17P2566.061.65
17Proline; L-ProlineAmino acids and derivatives; 0.73C5H9NO2115.061.53
18D-ProlineAmino acids and derivatives0.76C5H9NO2115.061.53
19LubiprostoneFatty acyls12.75C20H32F2O5390.221.40
20Phosphoric acidInganic acids0.65H3O4P97.981.29
21SarracineAlkaloids13.14C18H27NO5337.190.83
22Galactose 1-phosphateOrganooxygen compounds0.65C6H13O9P260.030.75
23L-Glutamic acidAmino acids and derivatives0.66C5H9NO4147.050.67
24KojibioseCarbohydrates0.72C12H22O11342.120.50
25Glucose 6-phosphateCarbohydrates0.65C6H13O9P260.030.49
26p-AminobenzoateBenzoic acid derivatives0.74C7H7NO2137.050.47
27BetaineAlkaloids1.06C5H11NO2117.080.47
28L-HistidineAmino acids and derivatives0.59C6H9N3O2155.070.44
298,9-DiHETrEFatty Acyls13.03C20H34O4338.250.43
30Gluconic acidOrganic acids0.69C6H12O7196.060.43
31N,N-DimethylglycineAmino acids and derivatives1.04C4H9NO2103.050.40
322-Aminoisobutyric acidAmino acids and derivatives0.98C4H9NO2103.060.37
33Diallyl disulfideOrganic disulfide0.68C6H10S2146.020.37
342-Hydroxybutanoic acidOrganic acids0.64C4H8O3104.050.35
35Beta-SitosterolSteroids12.93C29H50O414.390.33
36PhosphorylcholineCholines0.67C5H14NO4P183.070.31
37CampesterolSteroids and steroid derivatives12.18C28H48O400.370.31
38GemcitabinePyrimidine nucleosides0.75C9H11F2N3O4263.070.30
39L-ThreonineAmino acids and derivatives0.64C4H9NO3119.060.29
40L-HomoserineAmino acids and derivatives0.67C4H9NO3119.050.29
413-Ethyl-1,2-benzenediolPhenols0.74C8H10O2138.070.29
42DiacylglycerolGlycerolipids13.42C37H70O5568.510.28
43RutinFlavonoids5.85C27H30O16610.150.27
44cis-Aconitic acidOrganic acids and derivatives1.46C6H6O6174.020.25
45L-CitrulineAmino acids and derivatives0.66C6H13N3O3175.090.25
46WighteoneFlavonoids13.01C20H18O5338.110.24
47Beta-d-Fructose 2-phosphateCarbohydrates0.75C6H13O9P260.030.22
48MaltolFlavonoids0.90C6H6O3126.030.21
49Itaconic acidOrganic acids0.52C5H6O4130.030.21
50SafroleBenzodioxoles12.26C10H10O2162.070.20
5122-DehydroclerosterolSteroids12.59C29H46O410.350.18
528-HydroxybergaptenCoumarins10.56C12H8O5232.040.17
53IsoquercitrinFlavonoids6.06C21H20O12464.100.14
54MiltironeDiterpenoids12.98C19H22O2282.160.11
55PuerarinFlavonoids4.89C21H20O9416.110.11
56CinchonineAlkaloids11.99C19H22N2O294.170.09
573-Ethoxy-4-hydroxybenzaldehydePhenols5.72C9H10O3166.060.07
58LumichromeAlkaloids6.69C12H10N4O2242.080.07
Table 4. Major altered metabolic pathways in V. alginolyticus ATCC17749 treated by the CC1 from R. madaio Makino.
Table 4. Major altered metabolic pathways in V. alginolyticus ATCC17749 treated by the CC1 from R. madaio Makino.
Metabolic PathwayGene IDFold ChangeGene Description
Valine, leucine and isoleucine degradationN646_45852.117Acetoacetyl-coenzyme A synthetase
N646_45062.127Putative 3-hydroxyisobutyrate dehydrogenase
N646_40192.293Acetoacetyl-coenzyme A synthetase
N646_40492.793Putative acyl-CoA carboxyltransferase beta chain
N646_40473.123Putative acyl-CoA carboxylase alpha chain
N646_40573.3023-hydroxyisobutyrate dehydrogenase
N646_40484.128Putative enoyl-CoA hydratase/isomerase
N646_40534.602Putative aldehyde dehydrogenase
N646_40504.619Putative acyl-CoA dehydrogenase
Nitrogen metabolismN646_37272.193Putative oxidoreductase protein
N646_44262.656Hypothetical protein
N646_39155.506Periplasmic nitrate reductase
N646_43655.657Hypothetical protein
N646_39146.137Periplasmic nitrate reductase%2C cytochrome c-type protein
N646_436411.868Nitrite reductase [NAD(P)H]%2C small subunit
N646_101029.988Nitrite reductase periplasmic cytochrome c552
N646_023687.807Hydroxylamine reductase
Quorum sensingN646_03722.104ABC-type spermidine/putrescine transport system%2C permease component II
N646_22302.108Peptide ABC transporter%2C permease protein
N646_40262.258Putative ABC transporter%2C membrane spanning protein
N646_15762.315Peptide ABC transporter%2C periplasmic peptide-binding protein
N646_03792.493Oligopeptide ABC transporter%2C permease protein
N646_22282.531Peptide ABC transporter%2C periplasmic peptide-binding protein
N646_40272.666Putative high-affinity branched-chain amino acid transport permease protein
N646_03772.688Oligopeptide ABC transporter%2C ATP-binding protein
N646_15802.821Peptide ABC transporter%2C ATP-binding protein
N646_03782.836Oligopeptide ABC transporter%2C ATP-binding protein
N646_40242.850Putative high-affinity branched-chain amino acid transport ATP-binding protein
N646_03802.854Oligopeptide ABC transporter%2C permease protein
N646_40252.951Putative long-chain-fatty-acid-CoA ligase
N646_03813.075Oligopeptide ABC transporter%2C periplasmic oligopeptide-binding protein
N646_03703.909Putative ATP-binding component of ABC transporter
N646_40294.034Putative high-affinity branched-chain amino acid transport ATP-binding protein
N646_03714.049Putative permease of ABC transporter
N646_03674.112Putative binding protein component of ABC transporter
Histidine metabolismN646_03122.001Formimidoylglutamase
N646_01892.072Imidazoleglycerol-phosphate dehydratase/histidinol-phosphatase
N646_01902.090Imidazole glycerol phosphate synthase subunit HisH
N646_03133.141Imidazolonepropionase
N646_03113.168Urocanate hydratase
N646_03103.187Histidine ammonia-lyase
Fatty acid degradationN646_17530.344Hypothetical protein
N646_00662.033Amino acid ABC transporter%2C permease protein
N646_31452.064Rubredoxin/rubredoxin reductase
N646_22092.122Acetyl-CoA C-acyltransferase FadA
N646_31162.163Maltose ABC transporter periplasmic protein
N646_31172.319Maltose/maltodextrin ABC transporter%2C ATP-binding protein
N646_33892.793Putative ferrichrome ABC transporter (permease)
N646_13952.879Acyl-CoA dehydrogenase
N646_44293.400Nitrate ABC transporter nitrate-binding protein
N646_40285.585Hypothetical protein
N646_44276.398Hypothetical protein
N646_356814.448Putative ABC transporter%2C ATP-binding protein
ABC transportersN646_44852.173Arginine ABC transporter%2C permease protein
N646_45273.899Putative inner-membrane permease
N646_44874.958Arginine ABC transporter%2C periplasmic arginine-binding protein
N646_44885.676Arginine ABC transporter%2C ATP-binding protein
N646_44867.585ABC-type arginine transport system%2C permease component
Tryptophan metabolismN646_22102.123Fatty oxidation complex%2C alpha subunit
N646_36292.155Tryptophanase
N646_40525.154Putative acyl-CoA thiolase
Lysine degradationN646_36232.972Transcriptional regulator
N646_19793.332Arginine/lysine/ornithine decarboxylase
MAPK signaling pathwayN646_29090.123Cation transport ATPase%2C E1-E2 family protein
N646_31340.369Catalase
Glyoxylate and dicarboxylate metabolismN646_19652.122Acetyl-coenzyme A synthetase
N646_27412.135Isocitrate lyase
N646_27402.88Malate synthase
N646_36373.006Malate synthase
Amino sugar and nucleotide sugar metabolismN646_42260.400Glucose-1-phosphate adenylyltransferase
N646_15832.322Beta-N-hexosaminidase
N646_38342.610Hypothetical protein
N646_15823.440Ptative N-acetylglucosamine kinase
N646_43464.386Ptative mannose-6-phosphate isomerase
N646_34555.366Hpothetical protein
Table 5. Major altered metabolic pathways in V. parahaemolyticus ATCC17802 treated by the CC1 from R. madaio Makino.
Table 5. Major altered metabolic pathways in V. parahaemolyticus ATCC17802 treated by the CC1 from R. madaio Makino.
Metabolic PathwayGene IDFold ChangeGene Description
Methane metabolismVP_RS158650.091NapC/NirT family cytochrome c
VP_RS158600.067Trimethylamine-N-oxide reductase 2
VP_RS073250.224Acetate kinase
VP_RS139300.2062%2C3-bisphosphoglycerate-independent phosphoglycerate mutase
VP_RS181350.104Formate dehydrogenase subunit gamma
VP_RS126150.320Phosphate acetyltransferase
VP_RS073350.227Trimethylamine-N-oxide reductase TorA
VP_RS155850.304S-(hydroxymethyl)glutathione dehydrogenase/class III alcohol dehydrogenase
VP_RS056450.302Phosphoglycerate dehydrogenase
VP_RS073300.338Pentaheme c-type cytochrome TorC
VP_RS050300.381Molecular chaperone TorD
VP_RS155800.412S-formylglutathione hydrolase
VP_RS056400.3426-phosphofructokinase
Glycolysis/GluconeogenesisVP_RS232600.0876-phospho-beta-glucosidase
VP_RS129150.2726-phospho-beta-glucosidase
VP_RS122150.310Pyruvate dehydrogenase (acetyl-transferring)
VP_RS122100.331Pyruvate dehydrogenase complex dihydrolipoyllysine-residue acetyltransferase
VP_RS134100.406Glucose-6-phosphate isomerase
VP_RS104850.416D-hexose-6-phosphate mutarotase
VP_RS099100.433Pyruvate kinase
VP_RS182952.5582-oxo acid dehydrogenase subunit E2
Flagellar assemblyVP_RS225400.055Flagellar biosynthesis protein FliQ
VP_RS165400.064Flagellar basal body rod protein FlgB
VP_RS165650.086Flagellar basal-body rod protein FlgG
VP_RS225200.091OmpA family protein
VP_RS165500.129Flagellar hook assembly protein FlgD
VP_RS226050.193Flagellar motor stator protein MotA
VP_RS225450.210Flagellar biosynthetic protein FliR
VP_RS225750.225Flagellar filament capping protein FliD
VP_RS225350.237Flagellar type III secretion system pore protein FliP
VP_RS224900.265Flagellar protein export ATPase FliI
VP_RS165550.272Flagellar basal body protein FlgE
VP_RS225900.281Flagellar hook-length control protein FliK
VP_RS165750.327Flagellar basal body P-ring protein FlgI
VP_RS109200.363Flagellar M-ring protein FliF
VP_RS224950.366Flagellar assembly protein H
VP_RS109000.386Flagella biosynthesis chaperone FliJ
VP_RS165850.396Flagellar hook-associated protein FlgK
VP_RS165900.412Flagellar hook-associated protein FlgL
VP_RS137750.416Sel1 repeat family protein
VP_RS108350.429RNA polymerase sigma factor FliA
VP_RS108950.452Flagellar hook-length control protein FliK
VP_RS038350.462Flagellar hook protein FlgE
VP_RS038550.490Flagellar basal body P-ring protein FlgI
Glucagon signaling pathwayVP_RS017200.369Pyruvate kinase PykF
VP_RS183003.294Alpha-ketoacid dehydrogenase subunit beta
VP_RS229155.913Glycogen/starch/alpha-glucan phosphorylase
HIF-1 signaling pathwayVP_RS104800.168Type I glyceraldehyde-3-phosphate dehydrogenase
VP_RS147000.301ArsJ-associated glyceraldehyde-3-phosphate dehydrogenase
VP_RS126500.479Phosphoglycerate kinase
Nitrogen metabolismVP_RS202400.126Nitrite reductase large subunit NirB
VP_RS023100.158Glutamate synthase subunit beta
VP_RS202800.226Nitrate reductase
VP_RS023150.236Glutamate synthase large subunit
VP_RS202550.270ABC transporter substrate-binding protein
VP_RS121900.418Carbonate dehydratase
VP_RS209152.061Nitrate reductase cytochrome c-type subunit
VP_RS209102.197Periplasmic nitrate reductase subunit alpha
VP_RS0578014.974Hydroxylamine reductase
VP_RS0937019.809Ammonia-forming nitrite reductase cytochrome c552 subunit
Glycerolipid metabolismVP_RS017600.040Dihydroxyacetone kinase ADP-binding subunit DhaL
VP_RS017550.067Dihydroxyacetone kinase subunit DhaK
VP_RS212950.193Diacylglycerol kinase
VP_RS115800.239Glycerol kinase GlpK
VP_RS158100.431Glycerate kinase
VP_RS057402.015Triacylglycerol lipase
Apoptosis VP_RS232100.086Alkyl hydroperoxide reductase subunit C
VP_RS206500.282C-type cytochrome
VP_RS027950.415Peroxiredoxin C
Bacterial chemotaxisVP_RS226100.101OmpA family protein
VP_RS221600.243Methyl-accepting chemotaxis protein
VP_RS038150.255Protein-glutamate O-methyltransferase
VP_RS175850.267Methyl-accepting chemotaxis protein
VP_RS225000.294Flagellar motor switch protein FliG
VP_RS221000.337Methyl-accepting chemotaxis protein
VP_RS109150.356Flagellar motor switch protein FliG
VP_RS057600.374Methyl-accepting chemotaxis protein
VP_RS108200.386Chemotaxis protein CheA
VP_RS108250.389Protein phosphatase CheZ
VP_RS108800.411Flagellar motor switch protein FliN
VP_RS038100.415Chemotaxis protein CheV
VP_RS033050.433Flagellar motor protein PomA
VP_RS108150.471Chemotaxis response regulator protein-glutamate methylesterase
VP_RS108300.473Chemotaxis response regulator CheY
VP_RS053100.486Methyl-accepting chemotaxis protein
VP_RS108000.491Chemotaxis protein CheW
Propanoate metabolismVP_RS017500.051Glycerol dehydrogenase
VP_RS048550.072Formate C-acetyltransferase
VP_RS189850.119Acetyl-CoA carboxylase%2C carboxyltransferase subunit beta
VP_RS164050.240Aspartate aminotransferase family protein
VP_RS079302.0842-methylcitrate synthase
VP_RS079252.094Fe/S-dependent 2-methylisocitrate dehydratase AcnD
VP_RS205452.450CoA-acylating methylmalonate-semialdehyde dehydrogenase
Cationic antimicrobial peptide (CAMP) resistanceVP_RS002000.120Multidrug efflux RND transporter permease subunit VmeD
VP_RS002050.159Multidrug efflux RND transporter periplasmic adaptor subunit VmeC
VP_RS212600.344Thiol: disuLfide interchange protein DsbA/DsbL
VP_RS056700.456ATP-binding cassette domain-containing protein
VP_RS213000.489Phosphoethanolamine-lipid A transferase
VP_RS053152.030Multidrug efflux RND transporter periplasmic adaptor subunit VmeA
VP_RS208652.560Multidrug efflux RND transporter periplasmic adaptor subunit VmeY
VP_RS140654.124Envelope stress sensor histidine kinase CpxA
VP_RS140604.705Response regulator
Sulfur metabolismVP_RS070200.050Dimethyl sulfoxide reductase subunit A
VP_RS070300.052Dimethyl sulfoxide reductase anchor subunit
VP_RS070250.058Dimethyl sulfoxide reductase subunit B
VP_RS059300.110Cytochrome subunit of suLfide dehydrogenase
VP_RS039050.337Cysteine synthase A
VP_RS133700.417Assimilatory suLfite reductase (NADPH) hemoprotein subunit
VP_RS133750.440Assimilatory sulfite reductase (NADPH) flavoprotein subunit
VP_RS014350.442Sulfate adenylyltransferase subunit CysN
VP_RS014300.450Sulfate adenylyltransferase subunit CysD
Starch and sucrose metabolismVP_RS129200.206PTS lactose/cellobiose transporter subunit IIA
VP_RS191650.393Glucose-1-phosphate adenylyltransferase
VP_RS034100.474Alpha%2Calpha-phosphotrehalase
VP_RS230250.498Glycogen debranching protein GlgX
VP_RS034050.499PTS trehalose transporter subunit IIBC
VP_RS229104.6934-alpha-glucanotransferase
NecroptosisVP_RS040050.261Molecular chaperone HtpG
VP_RS005950.363Glutamate-ammonia ligase
Taurine and hypotaurine metabolismVP_RS101250.167Acetate kinase
VP_RS053700.219Alanine dehydrogenase
VP_RS101300.244Phosphate acetyltransferase
Benzoate degradationVP_RS206350.295Carboxymuconolactone decarboxylase family protein
VP_RS205502.679Thiolase family protein
VP_RS001352.713Fatty acid oxidation complex subunit alpha FadB
RNA transportVP_RS194300.440Stress response translation initiation inhibitor YciH
VP_RS019800.485Multifunctional CCA addition/repair protein
Phosphonate and phosphinate metabolismVP_RS164100.2062-aminoethylphosphonate--pyruvate Transaminase
VP_RS164000.491Phosphonoacetaldehyde hydrolase
Ethylbenzene degradationVP_RS107202.111Acetyl-CoA C-acyltransferase FadI
VP_RS001302.465Acetyl-CoA C-acyltransferase FadA
Biotin metabolismVP_RS054350.057Dethiobiotin synthase
VP_RS214150.265Beta-ketoacyl-ACP reductase
VP_RS054150.376Adenosylmethionine-8-amino-7-oxononanoate transaminase
VP_RS054250.4548-amino-7-oxononanoate synthase
VP_RS054200.479Biotin synthase BioB
VP_RS054300.492Malonyl-ACP O-methyltransferase BioC
VP_RS205202.061SDR family oxidoreductase
Table 6. Major altered metabolic pathways in V. parahaemolyticus B4-10 treated by the CC1 from R. madaio Makino.
Table 6. Major altered metabolic pathways in V. parahaemolyticus B4-10 treated by the CC1 from R. madaio Makino.
Metabolic PathwayGene IDFold ChangeGene Description
Styrene degradationVP_RS065500.394Homogentisate 1%2C2-dioxygenase
VP_RS065600.408Maleylacetoacetate isomerase
VP_RS065550.471Fumarylacetoacetate hydrolase family protein
Nitrogen metabolismVP_RS202402.129Nitrite reductase large subunit NirB
VP_RS198902.518Nitrite reductase small subunit NirD
VP_RS202352.823Nitrite reductase small subunit NirD
VP_RS202803.753Nitrate reductase
VP_RS209153.759Nitrate reductase cytochrome c-type subunit
VP_RS198953.988Nitrite reductase large subunit NirB
VP_RS209104.186Periplasmic nitrate reductase subunit alpha
VP_RS2025010.250ABC transporter permease
VP_RS0937029.586Ammonia-forming nitrite reductase cytochrome c552 subunit
VP_RS05780107.754Hydroxylamine reductase
Quorum sensingVP_RS065300.241Oligopeptide ABC transporter permease OppB
VP_RS065200.256ATP-binding cassette domain-containing protein
VP_RS065250.265ABC transporter permease subunit
VP_RS065150.297ATP-binding cassette domain-containing protein
VP_RS064850.310ABC transporter ATP-binding protein
VP_RS064950.346ABC transporter permease
VP_RS065350.362Peptide ABC transporter substrate-binding protein
VP_RS206700.368ABC transporter ATP-binding protein
VP_RS064900.370ABC transporter permease
VP_RS206800.381Branched-chain amino acid ABC transporter permease
VP_RS064700.388Polyamine ABC transporter substrate-binding protein
VP_RS210250.416Autoinducer 2-binding periplasmic protein LuxP
VP_RS206950.455ABC transporter ATP-binding protein
VP_RS016950.468Long-chain fatty acid--CoA ligase
VP_RS206750.475ABC transporter substrate-binding protein
VP_RS008500.495ABC transporter ATP-binding protein
VP_RS120502.098ABC transporter ATP-binding protein
VP_RS153052.117GTP cyclohydrolase II
VP_RS223152.159ABC transporter ATP-binding protein
VP_RS120402.232ABC transporter permease
VP_RS083602.551Two-component sensor histidine kinase
VP_RS220152.976Response regulator transcription factor
VP_RS083553.014Response regulator
VP_RS169303.141Permease
Folate biosynthesisVP_RS179750.476Phenylalanine 4-monooxygenase
VP_RS091300.494Aminodeoxychorismate synthase component I
VP_RS033650.491NADPH-dependent 7-cyano-7-deazaguanine reductase QueF
VP_RS078850.4977-cyano-7-deazaguanine synthase QueC
VP_RS091700.3896-carboxytetrahydropterin synthase QueD
VP_RS137300.433Aminodeoxychorismate/anthranilate synthase component II
VP_RS078900.4847-carboxy-7-deazaguanine synthase QueE
VP_RS179800.4324a-hydroxytetrahydrobiopterin dehydratase
VP_RS019700.4312-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase
Histidine metabolismVP_RS0618510.231Urocanate hydratase
VP_RS061806.284Histidine ammonia-lyase
VP_RS061956.998Imidazolonepropionase
VP_RS061905.106Formimidoylglutamase
VP_RS055650.496Bifunctional phosphoribosyl-AMP cyclohydrolase/phosphoribosyl-ATP diphosphatase HisIE
Table 7. Major altered metabolic pathways in B. cereus A1-1 treated by the CC1 from R. madaio Makino.
Table 7. Major altered metabolic pathways in B. cereus A1-1 treated by the CC1 from R. madaio Makino.
Metabolic PathwayGene IDFold ChangeGene Description
Flagellar assemblyBCN_RS085550.038Flagellar assembly protein FliH
BCN_RS086050.045Flagellin
BCN_RS086100.072Flagellin
BCN_RS086400.108Flagellar type III secretion system pore protein FliP
BCN_RS085500.113Flagellar motor switch protein FliG
BCN_RS222650.115Flagellar motor stator protein MotA
BCN_RS222600.143Flagellar motor protein MotB
BCN_RS085450.154Flagellar M-ring protein FliF
BCN_RS084700.158Flagellar motor switch protein
BCN_RS085600.158Flagellar protein export ATPase FliI
BCN_RS085350.173Flagellar basal body rod protein FlgC
BCN_RS086700.188Flagellar basal-body rod protein FlgG
BCN_RS085200.196Flagellar protein FliS
BCN_RS085300.197Flagellar basal body rod protein FlgB
BCN_RS086250.200Flagellar motor switch protein FliM
BCN_RS086600.230Flagellar biosynthesis protein FlhA
BCN_RS085100.241Flagellar hook-associated protein 3
BCN_RS086550.392Flagellar type III secretion system protein FlhB
BCN_RS086500.438Flagellar type III secretion system protein FliR
Bacterial chemotaxisBCN_RS100100.063Methyl-accepting chemotaxis protein
BCN_RS036750.088Methyl-accepting chemotaxis protein
BCN_RS022800.185Methyl-accepting chemotaxis protein
BCN_RS084600.186Response regulator
BCN_RS086250.200Flagellar motor switch protein FliM
BCN_RS251600.265DUF4077 domain-containing protein
BCN_RS249750.321Methyl-accepting chemotaxis protein
BCN_RS085950.357Chemotaxis protein
BCN_RS084550.474OmpA family protein
Two-component systemBCN_RS270050.136Respiratory nitrate reductase subunit gamma
BCN_RS261900.152Cytochrome d ubiquinol oxidase subunit II
BCN_RS237100.219Potassium-transporting ATPase subunit KdpA
BCN_RS270000.231Acetyl-CoA C-acyltransferase
BCN_RS237150.258Methyl-accepting chemotaxis protein
BCN_RS040800.385Nitrate reductase molybdenum cofactor assembly chaperone
BCN_RS150800.401Response regulator
BCN_RS040900.419Methyl-accepting chemotaxis protein
BCN_RS075052.006Phosphate ABC transporter substrate-binding protein PstS
BCN_RS265402.297Cytochrome ubiquinol oxidase subunit I
BCN_RS172902.348Chemotaxis protein CheA
BCN_RS027003.703Antiholin-like murein hydrolase modulator LrgA
BCN_RS107954.600Acetyl-CoA C-acetyltransferase
BCN_RS074955.804Hypothetical protein
Thiamine metabolismBCN_RS294650.031TenA family transcriptional regulator
BCN_RS023650.205Thiamine phosphate synthase
BCN_RS040050.224Thiaminase II
BCN_RS040400.274Thiazole synthase
BCN_RS040300.282Glycine oxidase ThiO
BCN_RS040500.304Bifunctional hydroxymethylpyrimidine kinase/phosphomethylpyrimidine kinase
BCN_RS040250.310Thiazole tautomerase TenI
BCN_RS259350.320Phosphomethylpyrimidine synthase ThiC
BCN_RS214850.342Alkaline phosphatase
BCN_RS126950.397Thiaminase II
BCN_RS023600.407Hydroxyethylthiazole kinase
BCN_RS100050.407Ribosome small subunit-dependent GTPase A
BCN_RS229550.433Cysteine desulfurase
BCN_RS026600.457Acetylornithine deacetylase
ABC transportersBCN_RS031300.051Amino acid ABC transporter permease
BCN_RS141250.051Glycine betaine ABC transporter substrate-binding protein
BCN_RS158950.056Substrate-binding domain-containing protein
BCN_RS069200.179ABC transporter ATP-binding protein
BCN_RS178800.205Ribose ABC transporter ATP-binding protein RbsA
BCN_RS011100.221Amino acid ABC transporter ATP-binding protein
BCN_RS069150.225Peptide ABC transporter substrate-binding protein
BCN_RS011000.258Amino acid ABC transporter ATP-binding protein
BCN_RS040100.263Phosphate ABC transporter permease PstA
BCN_RS087700.268Peptide ABC transporter substrate-binding protein
BCN_RS141200.268BMP family protein
BCN_RS205150.272ABC transporter ATP-binding protein
BCN_RS038550.278Phosphonate ABC transporter ATP-binding protein
BCN_RS011650.282Molybdate ABC transporter permease subunit
BCN_RS205250.283ABC transporter ATP-binding protein
BCN_RS211000.320Metal ABC transporter substrate-binding protein
BCN_RS040200.322ABC transporter substrate-binding protein
BCN_RS040150.326Phosphate ABC transporter permease subunit PstC
BCN_RS038450.330ATP-binding cassette domain-containing protein
BCN_RS038500.347Phosphate ABC transporter ATP-binding protein
BCN_RS246550.347Transporter substrate-binding domain-containing protein
BCN_RS011250.351Putative 2-aminoethylphosphonate ABC transporter ATP-binding protein
BCN_RS205200.355Aliphatic sulfonate ABC transporter substrate-binding protein
BCN_RS183350.379Iron ABC transporter permease
BCN_RS093500.405Energy-coupling factor transporter transmembrane protein EcfT
BCN_RS246650.405Putative 2-aminoethylphosphonate ABC transporter substrate-binding protein
BCN_RS011600.413Molybdate ABC transporter substrate-binding protein
BCN_RS047500.458ABC transporter permease
BCN_RS018700.465ABC transporter permease
BCN_RS177550.470Methionine ABC transporter substrate-binding lipoprotein MetQ
BCN_RS036000.487Phosphate ABC transporter substrate-binding protein PstS
BCN_RS095700.487Peptide ABC transporter substrate-binding protein
BCN_RS100850.487Sugar ABC transporter permease
BCN_RS096404.508Thiol reductant ABC exporter subunit CydC
BCN_RS2609014.65ABC transporter substrate-binding protein
BCN_RS1349520.285MetQ/NlpA family ABC transporter substrate-binding protein
Arginine biosynthesisBCN_RS204200.070N-acetyl-gamma-glutamyl-phosphate reductase
BCN_RS204000.117Ornithine carbamoyltransferase
BCN_RS204100.159Acetylglutamate kinase
BCN_RS204050.171Acetylornithine transaminase
BCN_RS204150.271Bifunctional glutamate N-acetyltransferase/amino-acid acetyltransferase ArgJ
BCN_RS009450.281Arginase
BCN_RS228600.292Argininosuccinate lyase
BCN_RS228650.486Argininosuccinate synthase
Nitrogen metabolismBCN_RS071500.365Nitronate monooxygenase
BCN_RS108355.001Nitrate transporter NarK
BCN_RS107906.281Nitrate reductase subunit beta
BCN_RS108007.880Respiratory nitrate reductase subunit gamma
BCN_RS107858.675Nitrate reductase subunit alpha
BCN_RS108708.912Nitrite reductase small subunit NirD
BCN_RS1087515.156NADPH-nitrite reductase large subunit
BCN_RS16540150.780Hydroxylamine reductase
Riboflavin metabolismBCN_RS203103.325Bifunctional diaminohydroxyphosphoribosylaminopyrimidine deaminase/5-Amino-6-(5-phosphoribosylamino) uracil reductase RibD
BCN_RS203204.247Bifunctional 3%2C4-dihydroxy-2-butanone 4-phosphate synthase/GTP Cyclohydrolase II
BCN_RS203254.3616%2C7-dimethyl-8-ribityllumazine synthase
BCN_RS203154.769Riboflavin synthase subunit alpha
Pyrimidine metabolismBCN_RS151250.3045’-nucleotidase C-terminal domain-containing protein
BCN_RS246250.355Bifunctional metallophosphatase/5’-nucleotidase
BCN_RS188150.381Carbamoyl-phosphate synthase large subunit
BCN_RS188200.406Carbamoyl phosphate synthase small subunit
BCN_RS187950.419Orotate phosphoribosyltransferase
BCN_RS188050.430Dihydroorotate oxidase B catalytic subunit
BCN_RS188000.438Orotidine-5’-phosphate decarboxylase
BCN_RS188100.441Dihydroorotate oxidase B electron transfer subunit
BCN_RS202650.4455’-nucleotidase C-terminal domain-containing protein
BCN_RS188250.449Dihydroorotase
BCN_RS078950.462Nucleoside-diphosphate kinase
BCN_RS094400.473Pyrimidine-nucleoside phosphorylase
HIF-1 signaling pathwayBCN_RS247250.191L-lactate dehydrogenase
BCN_RS254052.598Phosphoglycerate kinase
BCN_RS254102.736Type I glyceraldehyde-3-phosphate dehydrogenase
BCN_RS253903.143phosphopyruvate hydratase
BCN_RS240955.531L-lactate dehydrogenase
Fatty acid degradationBCN_RS174450.340Acetyl-CoA C-acetyltransferase
BCN_RS174500.456Acyl-CoA synthetase
Alanine, aspartate and glutamate metabolismBCN_RS088450.353Glutaminase A
BCN_RS088550.361Hypothetical protein
BCN_RS199050.420Carbon-nitrogen family hydrolase
BCN_RS150300.486Asparaginase
BCN_RS033050.498Aspartate ammonia-lyase
BCN_RS009702.986Glutamine--fructose-6-phosphate transaminase (isomerizing)
BCN_RS032307.200Alanine dehydrogenase
Benzoate degradationBCN_RS265352.1913-hydroxybutyryl-CoA dehydrogenase
BCN_RS247802.199Acetyl-CoA C-acetyltransferase
BCN_RS247852.2853-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase family protein
Glycolysis/GluconeogenesisBCN_RS088150.225Histidine phosphatase family protein
BCN_RS216000.299Bifunctional acetaldehyde-CoA/alcohol dehydrogenase
BCN_RS112850.411Alcohol dehydrogenase AdhP
BCN_RS282750.413S-(hydroxymethyl)glutathione dehydrogenase/class III alcohol dehydrogenase
BCN_RS229400.489Acyl-CoA ligase
BCN_RS264202.666PTS glucose transporter subunit IIA
BCN_RS253952.9012%2C3-bisphosphoglycerate-independent phosphoglycerate mutase
BCN_RS258155.5616-phospho-beta-glucosidase
Inositol phosphate metabolismBCN_RS181550.186Phosphatidylinositol diacylglycerol-lyase
BCN_RS036400.245Phospholipase C
BCN_RS254002.616Triose-phosphate isomerase
Butanoate metabolismBCN_RS027500.158Formate C-acetyltransferase
BCN_RS073050.199Acetolactate synthase large subunit
BCN_RS114100.359Acetate CoA-transferase subunit alpha
BCN_RS114150.382CoA transferase subunit B
BCN_RS048002.474Alpha-acetolactate decarboxylase
Propanoate metabolismBCN_RS185550.407ADP-forming succinate--CoA ligase subunit beta
BCN_RS079950.451Methylglyoxal synthase
BCN_RS185500.467Succinate-CoA ligase subunit alpha
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Liu, Y.; Yang, L.; Liu, P.; Jin, Y.; Qin, S.; Chen, L. Identification of Antibacterial Components in the Methanol-Phase Extract from Edible Herbaceous Plant Rumex madaio Makino and Their Antibacterial Action Modes. Molecules 2022, 27, 660. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27030660

AMA Style

Liu Y, Yang L, Liu P, Jin Y, Qin S, Chen L. Identification of Antibacterial Components in the Methanol-Phase Extract from Edible Herbaceous Plant Rumex madaio Makino and Their Antibacterial Action Modes. Molecules. 2022; 27(3):660. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27030660

Chicago/Turabian Style

Liu, Yue, Lianzhi Yang, Pingping Liu, Yinzhe Jin, Si Qin, and Lanming Chen. 2022. "Identification of Antibacterial Components in the Methanol-Phase Extract from Edible Herbaceous Plant Rumex madaio Makino and Their Antibacterial Action Modes" Molecules 27, no. 3: 660. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27030660

Article Metrics

Back to TopTop